<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348074</url>
  </required_header>
  <id_info>
    <org_study_id>HGH20090520</org_study_id>
    <nct_id>NCT01348074</nct_id>
  </id_info>
  <brief_title>Reinitiation of Anticoagulation After Temporary Withdrawal of Vitamin K Antagonist</brief_title>
  <acronym>DOSIDO</acronym>
  <official_title>Phase II Study of Double Versus Single Reinitiation Dose of Warfarin After Interruption for Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is not known how to best restart warfarin after temporary withdrawal. Participants will be
      randomized to two groups. Group 1 will restart warfarin at their usual maintenance dose,
      group 2 will restart warfarin at double their maintenance dose for two days followed by their
      usual maintenance dose. The main outcome parameter will be the number of patients who are
      back in therapeutic INR (international normalized ratio) range 4, and 9 days after restarting
      anticoagulation with warfarin. Thromboembolic and/or bleeding events will be recorded as
      additional parameters. These data will be collected by a standardized telephone interview at
      1 month. In addition, the investigators will evaluate a possible prothrombotic state by
      measuring the potential of thrombin generation and D-dimers in the subset of patients
      visiting HHS-General Hospital for their INR tests.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will investigate if it is feasible to use double maintenance dose for the first two
      administrations of vitamin K antagonists when these drugs were temporarily interrupted and
      thus keep the time of an increased risk of thromboembolism and duration of &quot;bridging&quot; at a
      minimum. The control group will consist of patients who resume vitamin K antagonists at their
      usual maintenance dose. The aim of the study is to establish how to best restart
      anticoagulation with vitamin K antagonists after temporal withdrawal of these drugs. The main
      outcome parameter will be the proportion of patients who are back to a therapeutic
      international normalized ratio (INR) ratio at certain days after restarting vitamin K
      antagonists. Two additional parameters will be evaluated: Firstly, bleeding and
      thromboembolic complications will be reported and secondly, a possible prothrombotic state,
      measured as an elevation of D-dimer, at the initiation of anticoagulation will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with INR back in therapeutic range Day 5 or Day 10</measure>
    <time_frame>Day 5-10</time_frame>
    <description>Proportion of patients with INR 2.0-3.0 on Day 5 or Day 10 (day of invasive procedure defined as Day 1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic events</measure>
    <time_frame>30 days</time_frame>
    <description>Objectively verified arterial or venous thromboembolic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding events</measure>
    <time_frame>30 days</time_frame>
    <description>Defined by the ISTH criteria of 2010</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor bleeding events</measure>
    <time_frame>30 days</time_frame>
    <description>Any bleeding requiring medical attention but not fulfilling the criteria of Major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters of hypercoagulability</measure>
    <time_frame>10 days</time_frame>
    <description>Quantitative D-dimer and Thrombin Generation performed in a subset at day of procedure, day 5 and 10 to identify abnormal rise.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Heart Valve Disease</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Double dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Re-initiation with warfarin at twice the usual maintenance dose the first 2 days, then maintenance dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual maintenance dose</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual maintenance dose from Day 1, i.e. no postoperative loading dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double dose</intervention_name>
    <description>For each individual the dose on Day 1 and Day 2 will be twice the one normally taken</description>
    <arm_group_label>Double dose</arm_group_label>
    <other_name>Loading dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current treatment with warfarin

          -  Need for temporary interruption for invasive procedure or surgery

        Exclusion Criteria:

          -  Need for post-operative hospitalization more than one day

          -  Participation in another clinical trial

          -  No consent given
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Schulman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thrombosis Service, HHS- General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1111/jth.12613/abstract</url>
    <description>Published article on this study</description>
  </link>
  <reference>
    <citation>Schulman S, El Bouazzaoui B, Eikelboom JW, Zondag M. Clinical factors influencing the sensitivity to warfarin when restarted after surgery. J Intern Med. 2008 Apr;263(4):412-9. doi: 10.1111/j.1365-2796.2007.01913.x. Epub 2008 Jan 16.</citation>
    <PMID>18205763</PMID>
  </reference>
  <results_reference>
    <citation>Schulman S, Hwang HG, Eikelboom JW, Kearon C, Pai M, Delaney J. Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. J Thromb Haemost. 2014 Aug;12(8):1254-9. doi: 10.1111/jth.12613. Epub 2014 Jun 25.</citation>
    <PMID>24837794</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>April 1, 2016</last_update_submitted>
  <last_update_submitted_qc>April 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Sam Schulman</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>warfarin</keyword>
  <keyword>surgery</keyword>
  <keyword>management</keyword>
  <keyword>thromboembolism</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

